Cardiol Therapeutics Achieves Target Patient Enrollment in its Phase II ARCHER Trial Investigating CardiolRx(TM) for Acute Myocarditis
Cardiol Therapeutics (NASDAQ: CRDL) announced the completion of target patient enrollment for its Phase II ARCHER trial, evaluating CardiolRx™ in acute myocarditis. The trial, with 100 patients from five countries, aims to assess the safety, tolerability, and impact of CardiolRx™ on myocardial recovery. Primary outcomes include measures of left ventricular function and myocardial edema/fibrosis, with topline results expected early next year. This milestone complements data from the MAvERIC Phase II study on recurrent pericarditis, to be presented in November. Acute myocarditis, a severe inflammatory heart disease, lacks FDA-approved therapies, presenting a significant opportunity for Cardiol.
Cardiol Therapeutics (NASDAQ: CRDL) ha annunciato il completamento dell'arruolamento dei pazienti target per il suo trial di Fase II ARCHER, che valuta CardiolRx™ nell'infiammazione acuta del miocardio. Lo studio, che coinvolge 100 pazienti provenienti da cinque paesi, mira a valutare la sicurezza, la tollerabilità e l'impatto di CardiolRx™ sul recupero miocardico. Gli esiti principali includono misure della funzione del ventricolo sinistro e dell'edema/fibrosi miocardica, con risultati preliminari attesi all'inizio del prossimo anno. Questo traguardo si aggiunge ai dati dello studio MAvERIC di Fase II sulla pericardite ricorrente, che saranno presentati a novembre. L'infiammazione acuta del miocardio, una grave malattia infiammatoria cardiaca, è priva di terapie approvate dalla FDA, offrendo un'opportunità significativa per Cardiol.
Cardiol Therapeutics (NASDAQ: CRDL) anunció la finalización del reclutamiento de pacientes objetivos para su ensayo de Fase II ARCHER, que evalúa CardiolRx™ en la miocarditis aguda. El ensayo, que incluye a 100 pacientes de cinco países, tiene como objetivo evaluar la seguridad, la tolerancia y el impacto de CardiolRx™ en la recuperación miocárdica. Los resultados primarios incluyen medidas de la función del ventrículo izquierdo y del edema/fibrosis miocárdica, con resultados preliminares esperados a principios del próximo año. Este hito complementa los datos del estudio MAvERIC de Fase II sobre la pericarditis recurrente, que se presentarán en noviembre. La miocarditis aguda, una grave enfermedad cardíaca inflamatoria, carece de terapias aprobadas por la FDA, lo que presenta una oportunidad significativa para Cardiol.
Cardiol Therapeutics (NASDAQ: CRDL)는 급성 심근염에서 CardiolRx™를 평가하는 II상 ARCHER 시험의 목표 환자 등록 완료를 발표했습니다. 5개국에서 100명의 환자가 모집된 이 시험은 CardiolRx™의 안전성, 내약성 및 심장 회복에 미치는 영향을 평가하는 것을 목표로 합니다. 주요 결과에는 좌심실 기능 및 심근 부종/섬유화 측정이 포함되며, 내년 초에 주요 결과가 발표될 예정입니다. 이 이정표는 11월에 발표될 반복성 심낭염에 대한 MAvERIC II상 연구의 데이터를 보완합니다. 급성 심근염은 심각한 염증성 심장 질환으로 FDA 승인을 받은 치료제가 없어 Cardiol에 중요한 기회를 제공합니다.
Cardiol Therapeutics (NASDAQ: CRDL) a annoncé l'achèvement du recrutement des patients cibles pour son essai de phase II ARCHER, évaluant CardiolRx™ dans le cadre de myocardite aiguë. L'essai, impliquant 100 patients de cinq pays, vise à évaluer la sécurité, la tolérance et l'impact de CardiolRx™ sur la récupération myocardique. Les résultats principaux incluent des mesures de la fonction ventriculaire gauche et de l'œdème/fibrose myocardique, avec des résultats préliminaires attendus au début de l'année prochaine. Cette étape vient compléter les données de l'étude MAvERIC de phase II sur la péricardite récurrente, qui seront présentées en novembre. La myocardite aiguë, une maladie cardiaque inflammatoire grave, ne dispose d'aucun traitement approuvé par la FDA, offrant une opportunité significative pour Cardiol.
Cardiol Therapeutics (NASDAQ: CRDL) hat den Abschluss der Rekrutierung von Zielpatienten für die Phase II ARCHER-Studie bekannt gegeben, die CardiolRx™ bei akuter Myokarditis evaluiert. Die Studie umfasst 100 Patienten aus fünf Ländern und zielt darauf ab, die Sicherheit, Verträglichkeit und den Einfluss von CardiolRx™ auf die myokardiale Erholung zu bewerten. Zu den primären Endpunkten gehören Messungen der Funktion des linken Ventrikels sowie von Myokardödem/Fibrose, wobei erste Ergebnisse für Anfang nächsten Jahres erwartet werden. Dieser Meilenstein ergänzt die Daten aus der MAvERIC Phase II-Studie zur wiederkehrenden Perikarditis, die im November präsentiert werden sollen. Akute Myokarditis, eine schwerwiegende entzündliche Herzerkrankung, verfügt über keine von der FDA genehmigten Therapien und bietet Cardiol eine bedeutende Gelegenheit.
- Completion of target patient enrollment for Phase II ARCHER trial.
- Topline results expected early next year.
- Potential for orphan drug designation in the US and EU.
- No FDA-approved therapies for acute myocarditis, indicating high-risk development.
Insights
The completion of target patient enrollment in Cardiol Therapeutics' ARCHER trial is a significant milestone in the development of CardiolRx™ for acute myocarditis. This Phase II randomized, double-blind, placebo-controlled study with 100 patients aims to evaluate the drug's impact on myocardial recovery.
Key points to consider:
- The trial's primary outcome measures include left ventricular function and myocardial edema/fibrosis, which are predictive of long-term prognosis.
- Topline results are expected early next year, potentially providing important insights into CardiolRx™'s efficacy.
- Acute myocarditis is a serious condition with no FDA-approved therapies, representing a significant unmet medical need.
- The potential for orphan drug designation could provide marketing exclusivity and accelerated regulatory review, enhancing the drug's market potential.
While the completion of enrollment is promising, investors should remain cautious as Phase II results are still pending. The outcome of this trial could significantly impact Cardiol Therapeutics' future prospects and valuation.
Toronto, Ontario--(Newsfile Corp. - September 24, 2024) - Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) ("Cardiol" or the "Company"), a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, today announced it has achieved the target patient enrollment of 100 patients in "ARCHER", its Phase II randomized, double-blind, placebo-controlled trial evaluating the impact of CardiolRx™ on myocardial recovery in patients with acute myocarditis.
"We are pleased to have achieved our target patient enrollment in the ARCHER trial, which reflects the commitment and dedication of our clinical collaborators and participating patients. Reaching this milestone is integral to enhancing our understanding of the therapeutic impact of CardiolRx™ in acute myocarditis, a debilitating and potentially life-threatening inflammatory heart disease that significantly impairs cardiac function and patient quality of life," said Andrew Hamer, Cardiol Therapeutics' Chief Medical Officer and Head of Research & Development. "With topline results expected early next year the data from the ARCHER trial is anticipated to offer key insights concerning the effects of CardiolRx™ on myocardial recovery. Furthermore, we anticipate these findings will complement the clinical data from our MAvERIC Phase II study in recurrent pericarditis, the full results of which will be presented in November at the American Heart Association Scientific Sessions 2024."
ARCHER Study Design
The design and rationale for ARCHER were published June 27, 2024, in the journal ESC Heart Failure. ARCHER is a Phase II multi-national, randomized, double-blind, placebo-controlled trial investigating the safety, tolerability, and impact of CardiolRx™ on myocardial recovery in patients presenting with acute myocarditis. The study has an enrollment target of 100 patients to be recruited from pre-eminent cardiovascular research centers in the United States, Canada, France, Brazil, and Israel. The primary outcome measures of the trial, which will be evaluated following 12 weeks of double-blind therapy, consist of two cardiac magnetic resonance imaging measures: left ventricular function (longitudinal strain) and myocardial edema/fibrosis (extra-cellular volume), each of which has been shown to predict long-term prognosis of patients with acute myocarditis. Additional efficacy outcome measurements include survival, freedom from major cardiovascular events, resolution of clinical symptoms, and change in biomarkers associated with cardiac function and inflammation.
Acute Myocarditis
Acute myocarditis is an inflammatory condition of the heart muscle (myocardium) characterized by chest pain, shortness of breath at rest or during activity, fatigue, rapid or irregular heartbeat (arrhythmias), and light-headedness or the feeling one might faint. The disease is an important cause of acute and fulminant heart failure and is a leading cause of sudden cardiac death in people under 35 years of age. Viral infection is the most common cause of myocarditis; however, it can also result from bacterial infection and commonly used drugs and mRNA vaccines, as well as therapies used to treat several common cancers, including chemo-therapeutic agents and immune checkpoint inhibitors. There are no FDA-approved therapies for acute myocarditis. Patients hospitalized with the condition experience an average seven-day length of stay and a 4 -
Cardiol believes there is a significant opportunity to develop an important new therapy for acute myocarditis that would also be eligible for designation as an orphan drug in the United States and the European Union. Orphan drug designation programs were established to provide life sciences companies with incentives to develop new therapies for rare diseases. These incentives include periods of prolonged marketing exclusivity and exemptions from certain fees. Products with orphan drug designation also frequently qualify for accelerated regulatory review.
About Cardiol Therapeutics
Cardiol Therapeutics Inc. (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company's lead small molecule drug candidate, CardiolRx™ (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease. It is recognized that cannabidiol inhibits activation of the inflammasome pathway, an intracellular process known to play an important role in the development and progression of inflammation and fibrosis associated with myocarditis, pericarditis, and heart failure.
Cardiol has received Investigational New Drug Application authorization from the United States Food and Drug Administration ("US FDA") to conduct clinical studies to evaluate the efficacy and safety of CardiolRx™ in two diseases affecting the heart: (i) a Phase II multi-center open-label pilot study in recurrent pericarditis (the MAvERIC-Pilot study; NCT05494788), an inflammatory disease of the pericardium which is associated with symptoms including debilitating chest pain, shortness of breath, and fatigue, and results in physical limitations, reduced quality of life, emergency department visits, and hospitalizations; and (ii) a Phase II multi-national, randomized, double-blind, placebo-controlled trial (the ARCHER trial; NCT05180240) in acute myocarditis, an important cause of acute and fulminant heart failure in young adults and a leading cause of sudden cardiac death in people less than 35 years of age. The US FDA has granted Orphan Drug Designation to CardiolRx™ for the treatment of pericarditis, which includes recurrent pericarditis.
Cardiol is also developing CRD-38, a novel subcutaneously administered drug formulation intended for use in heart failure - a leading cause of death and hospitalization in the developed world, with associated healthcare costs in the United States exceeding
For more information about Cardiol Therapeutics, please visit cardiolrx.com.
Cautionary statement regarding forward-looking information:
This news release contains "forward-looking information" within the meaning of applicable securities laws. All statements, other than statements of historical fact, that address activities, events, or developments that Cardiol believes, expects, or anticipates will, may, could, or might occur in the future are "forward-looking information". Forward looking information contained herein may include, but is not limited to, statements relating to the Company's focus on developing anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease, the molecular targets and mechanism of action of the Company's product candidates, the Company's intended clinical studies and trial activities and timelines associated with such activities, including for primary efficacy endpoint and secondary endpoints, the Company's anticipation that the results of the ARCHER trial are anticipated to offer key insights concerning the effects of CardiolRx™ on myocardial recovery, the Company's expectation that the results of the ARCHER trial will complement the Company's clinical data from the MAvERIC Phase II study in recurrent pericarditis, the Company's plans to present the full results of the MAvERIC Phase II study in November 2024 at the American Heart Association Scientific Sessions 2024, the Company's expectation that there is a significant opportunity to develop an important new therapy for acute myocarditis that would also be eligible for designation as an orphan drug in the United States and the European Union, and the Company's plan to advance the development of CRD-38, a novel subcutaneous formulation of cannabidiol intended for use in heart failure. Forward-looking information contained herein reflects the current expectations or beliefs of Cardiol based on information currently available to it and is based on certain assumptions and is also subject to a variety of known and unknown risks and uncertainties and other factors that could cause the actual events or results to differ materially from any future results, performance or achievements expressed or implied by the forward-looking information, and are not (and should not be considered to be) guarantees of future performance. These risks and uncertainties and other factors include the risks and uncertainties referred to in the Company's Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission and Canadian securities regulators on April 1, 2024, as well as the risks and uncertainties associated with product commercialization and clinical studies. These assumptions, risks, uncertainties, and other factors should be considered carefully, and investors should not place undue reliance on the forward-looking information, and such information may not be appropriate for other purposes. Any forward-looking information speaks only as of the date of this press release and, except as may be required by applicable securities laws, Cardiol disclaims any intent or obligation to update or revise such forward-looking information, whether as a result of new information, future events, or results, or otherwise.
For further information, please contact:
Trevor Burns, Investor Relations +1-289-910-0855
trevor.burns@cardiolrx.com
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/224343
FAQ
What is the purpose of Cardiol Therapeutics' ARCHER trial?
When are the topline results of the ARCHER trial expected?
What are the primary outcomes measured in the ARCHER trial?
What is the significance of acute myocarditis?
What opportunity does Cardiol see in treating acute myocarditis?
